Pharmamarketeer
overig

Merck’s Keytruda nabs new data to rival Bristol-Myers’ Opdivo at fending off melanoma’s return

15 januari 2018
FiercePharma

Merck & Co. and Bristol-Myers Squibb have been head-to-head competitors in melanoma ever since their two immuno-oncology treatments, Keytruda and Opdivo, both won their first FDA approvals. Now, with its latest data, Keytruda can play catch-up with its rival for another new use.

Reageer

Ook interessant voor je

Medhc-fases-banner
Advertentie(s)